Mednet Logo

What is your approach for locoregional mediastinal recurrence of NSCLC adenocarcinoma in fit patients >5 years from definitive treatment (chemoradiation and/or surgery)?

Would this approach be different for a patient treated with tri-modality therapy (ie neoadjuvant chemoradiation followed by resection)?
2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · UCSD Moores Cancer Center
Answered on

There are a lot of variables here including number of lymph node stations involved, bulky vs non bulky disease, and lung/cardiac function. I would treat this similar to de novo diagnosis given the timeframe from prior treatment as this is unlikely to be an isolated relapse this far out. Definitive c...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · Siri Onclogy and hematology Infusion Service
Answered on

I would consider this a late relapse if same histology. Given the prior radiation therapy, I would think toxicity would be great from radiation.

I would treat this as recurrent disease, and depending on histology and PDL1 status use immunotherapy +/- chemotherapy unless adenocarcinoma PDL- in which ...

Join for free or sign in to see the full answer